Allosteric modulation company Addex Pharmaceuticals announced that the company has been awarded EuropaBio’s Most Innovative SME Award. This is the first time that the award has been presented and it attracted applications by 32 companies from 12 countries representing all sectors of the biotech industry. Dr. Vincent Mutel, CEO of Addex said, We are honored to be the first ever recipients of this new EuropaBio innovation award. At Addex, we are building a sustainable business based on technology that brings a new kind of chemistry to industrial drug discovery efforts. By improving discovery productivity, a key bottleneck hindering the pharmaceutical industry, we may be able to address some of key obstacles that have prevented development of effective treatments for many diseases, including Parkinson’s and schizophrenia, for which our lead products are about to enter Phase II clinical evaluation.
